Clinton Lewis - Zoetis President

ZTS -- USA Stock  

USD 126.05  0.70  0.55%

  President
Mr. Clinton A. Lewis, Jr. is Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics of the Company. Mr. Lewis has served as our Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics and Aquatic Health since March 2018, and was given responsibility for Human Medical Diagnostics in January 2019. He previously served as our Executive Vice President and President, International Operations from May 2015 to February 2018. From October 2012 through April 2015, he served as our Executive Vice President and President of U.S. Operations, and from 2007 to 2012, he was President of U.S. Operations for Pfizer Animal Health, our predecessor company. Mr. Lewis joined Pfizer in 1988 and held various positions across sales, marketing and general management, including Senior Vice President of Sales, U.S. General Manager, Pfizer Caribbean and General Manager, U.S. AntiInfectives.
Age: 51  President Since 2018      
973-822-7000  http://www.zoetis.com
Lewis holds a bachelor degree in biology from Fairfield University and a MBA in marketing from Fairleigh Dickinson University.

Clinton Lewis Latest Insider Activity

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Michael AbermanRegeneron Pharmaceuticals
2015
Douglas BoothePerrigo Company plc
2013
Charles WagnerVertex Pharmaceuticals Incorpor
2019
George YancopoulosRegeneron Pharmaceuticals
2016
Svend AndersenPerrigo Company plc
2017
Christopher FenimoreRegeneron Pharmaceuticals
2017
Marion McCourtRegeneron Pharmaceuticals
2018
Michael PariniVertex Pharmaceuticals Incorpor
2017
Scott JamisonPerrigo Company plc
2011
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Samiran DasDr Reddys Laboratories Ltd
2016
Grainne QuinnPerrigo Company plc
2016
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
John GrayVertex Pharmaceuticals Incorpor
2019
Peter PowchikRegeneron Pharmaceuticals
2006
Thomas GraneyVertex Pharmaceuticals Incorpor
2017
M RamanaDr Reddys Laboratories Ltd
2018
Marc CouckePerrigo Company plc
N/A
Michael StewartPerrigo Company plc
2004

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive VP and President of U.S. Operations
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President
Linda Rhodes, Director
Frank DAmelio, Director
Robert Scully, Independent Director
Clinton Lewis, Executive VP and President of International Operations
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, President of RandD and Executive VP
Michael McCallister, Non-Executive Chairman of the Board
Paul Bisaro, Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Acting CFO and Sr. VP
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President CIO
Gregory Norden, Independent Director
Louise Parent, Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, CEO and Director

Stock Performance Indicators

Did you try this?

Run Risk-Return Analysis Now

   

Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
All  Next Launch Module

Also Currentnly Active

Purchased over 200 shares of
few hours ago
Traded for 36.01
Purchased over 90 shares of
few hours ago
Traded for 104.22
Purchased over 20 shares of
few hours ago
Traded for 198.03
See also Your Current Watchlist. Please also try Portfolio Reporting module to create custom reports across your portfolios and generate quick suggestion pitch.
Search macroaxis.com